Expect Integrase Inhibitors to Gain an Edge in Treating HIV

Updated guidelines will lead to a shift in preferred antiretroviral meds for treating HIV in adults.

Expect to see more HIV patients admitted on a regimen that includes integrase inhibitors...especially bictegravir (Biktarvy) or dolutegravir (Tivicay, etc) since they seem less likely to develop resistance.

That's because integrase inhibitors are often better tolerated than protease inhibitors, such as darunavir (Prezista, etc)...or NON-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz (Sustiva, etc).

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals